Dr. Dan Brennan talked about the importance of CMV infections in renal transplantation and in general population. Asymptomatic CMV increases mortality 4 yrs after transplantation with a RR of 2.6%. CMV is associated with MGUS, colorectal cancer, PTLD post transplant. He also talked in detail about the prophylactic and preemptive management of CMV infection post transplant.

Dr. Myles Wolf talked excellently about FGF 23 in detail on both first and second day. His review was outstanding. He explained the phosphate metabolism in CKD and how FGF 23 explains the whole picture. He also mentions that FGF 23 not PTH may be associated with hypophosphatemia post transplant. He also emphasizes on association of FGF 23 and mortality in CKD population and also on FGF 23 and cardiovascular disease in general population.

Dr. Kahan gave an excellent review of various intracellular targets of immunosuppressive agents in transplantation. He covered various drugs, mechanisms, use etc. Interestingly cumin, a spice use in Indian cooking has curcumin with immunosuppressive properties.

Dr. Shah gave a review of history of immunosuppresion. He then talked in detail about mycophenolate and tacrolimus. MPA dose reduction for GI side effects associated with increased risk of rejection and annual increase in graft loss.

Dr. Suki gave an excellent review on importance of phosphorus control in CKD and ESRD population. High phosphorus linked to increased risk of death in CKD, ESRD and CAD population. He indicated that use of non-calcium based binders may improve cardiovascular mortality as high calcium also may increase vascular calcification.

Dr. Shah gave a detailed review of Fabry’s disease. Though post renal transplant survival is good, Enzyme replacement therapy may improve quality of life and may improve other symptoms of the disease namely cardiovascular and neurological.

Dr. Helderman talked about that use of generic drugs in renal transplantation. He suggested that bioequivalence doesn’t mean therapeutic equivalence. Switching to generic drugs will need much closer monitoring of patients.